Method for determination of prognosis of prostate cancer, and diagnostic agent for use in the method
US8080384B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2007 |
| Grant date | Dec 20, 2011 |
| Priority date | — |
| Expiry date | Feb 11, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/57434
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method for determining probability that prostate cancer will metastasize, as well as a diagnostic reagent used therefor is disclosed. It was discovered that the percentage that NF-κB-p65/RelA has the 254th amino acid threonine which is phosphorylated is significantly higher in the prostate cancer cells in the cases where the bone metastasis was observed than in the cases where bone metastasis was not observed. Thus, the method for determining probability that prostate cancer will metastasize comprises measuring human NF-κB-p65/RelA in which 254th amino acid threonine is phosphorylated, which human NF-κB-p65/RelA is contained in a prostate tissue separated from human.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.